In November 2020, LLS made an equity investment in Abintus Bio to "Support in vivo CAR Development for Blood Cancers." Abintus plans to develop a portfolio of first-in-class product candidates that reprogram immune cells in vivo to eliminate tumors utilizing proprietary vectors and vector-engineering technologies to develop an in vivo chimeric antigen receptor (CAR) T platform based on a non-replicating gammaretrovirus.
Abintus is a private company based in San Diego, CA where the company is developing cutting-edge CAR therapies that allow for powerful CAR-T cells to be generated directly in a patient’s body, eliminating the need for time-consuming and costly collection, engineering and re-infusion of patient T-cells. This direct “in situ” approach within the native environment of the immune cells could have scientific advantages. The innovative Abintus approach aims to reprogram T-cells inside the body to attack and eliminate tumors. This technology is currently in preclinical testing and could, if successful, support immediate patient dosing, a substantial benefit for patients facing advanced forms of cancer with a poor prognosis. Abintus’ platform is versatile and scalable, so they have the potential to meet the needs of a much larger patient population.
The Abintus approach leverages a substantial body of clinical safety data that support the safety of their approach. As with any novel therapy, safety will continue to be carefully characterized and investigated. This project is in preclinical development with a goal to explore the products in blood cancers and solid tumors using this novel technology platform being developed by Abintus.
For more information about Abintus, visit www.abintusbio.com.
- Nov. 17, 2021 - announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center for the use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products.